Roche: approval in lung cancer in the United States
This approval is based on the ALINA phase III study showing that Alecensa reduces the risk of recurrence or death by an unprecedented 76% in people with ALK-positive NSCLC resected at an early stage.
It helps address an urgent unmet need, as around half of all people with early-stage NSCLC experience disease recurrence after surgery, despite adjuvant chemotherapy," says the Swiss healthcare group.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction